McGraw Hill Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $2.1B+0.7% YoYTTM through 30 Jun 2026
Net Income $92.7MTTM through 30 Jun 2026
Free Cash Flow $335.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 80.9% |
| EBITDA Margin | 30.8% |
| Operating Margin | 13.2% |
| Net Margin | 4.4% |
Returns
4.9%ROE
0.6%ROA
2.9%ROIC
Balance Sheet Health
Debt / Equity3.62x
Current Ratio0.78x
Net Debt$2.4B
Cash & Equivalents$193.6M
Quality Metrics
Altman Z-Score0.55
Piotroski F-Score7 / 9
FCF Margin15.9%
Rule of 4017.4
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2026: $2.1B
Diluted EPS$0.49TTMFY2026: $0.19
Dividend
No dividend
Capital Allocation
R&D Spend$270.6M
Capex Intensity4.4%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| K-12 | $884.5M | -8.9% | View detailsWell-positioned for multi-year growth via nationwide Science of Reading refresh starting in FY2027. |
| Higher Education | $879M | +12.3% | View detailsStrong momentum driven by Inclusive Access upsell and cross-sell opportunities. |
| Global Professional | $147.2M | View detailsGrowth driven by AI-powered medical solutions built on trusted content. | |
| International | $186.7M | -7.3% | View detailsMarket headwinds giving way to new commercial opportunities and global expansion of ALEKS Calculus. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.